ESC 365 - Doctor Safia Chatur

Speaker illustration

Doctor Safia Chatur

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

Member of:

Heart Failure Association

Trade-off of risk and benefit of finerenone across the spectrum of kidney function in patients with heart failure with mildly reduced and preserved ejection fraction in the FINEARTS-HF trial

Event: Heart Failure 2025

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Clinical trials updates in medical therapy

Finerenone in patients with heart failure and deterioration in eGFR to <25ml/min/1.73m2 in the FINEARTS-HF Trial

Event: Heart Failure 2025

Topic: Pharmacotherapy

Session: Tailored therapeutics advances in heart failure

Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: a participant level pooled analysis of CREDENCE and CANVAS

Event: ESC Congress 2024

Topic: Pharmacotherapy

Session: Modern views on worsening heart failure

Safety and efficacy of sacubitril/valsartan in patients with heart failure with mildly reduced or preserved EF after a worsening heart failure event based on diuretic use in PARAGLIDE-HF

Event: Heart Failure 2024

Topic: Pharmacotherapy

Session: Chronic heart failure - treatment 11

Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial

Event: ESC Congress 2023

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Insights from recent HFpEF trials 1

Dapagliflozin reduces loop diuretic requirement over time in patients with heart failure with mildly reduced or preserved ejection fraction in the DELIVER Trial

Event: Heart Failure 2023

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Pharmacotherapy

Renal and hemodynamic effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction in DELIVER

Event: Heart Failure 2023

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Chronic heart failure - pathophysiology 1

Effects of dapagliflozin on hospitalizations for heart failure according to severity of inpatient treatment course: the DELIVER Trial

Event: Heart Failure 2023

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Heart failure with preserved ejection fraction (HFpEF) 1

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources